Opus Genetics Inc (IRD) Stock Price, Quote & News

Company Profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs...

Industry: Biotechnology

Sector: Healthcare

Phone: 984 884 6030

Website: opusgtx.com

Address:

8 Davis Drive, Suite 220, Durham, United States

TheAliAbdul Jun. 5 at 6:02 PM

$IRD market is red today so this isn’t too unexpected, still disappointing to give up most of yesterdays gains.

0 · Reply

daytradernut Jun. 5 at 12:34 AM

$IRD

0 · Reply

retro123 Jun. 4 at 8:09 PM

$IRD beautiful close 🥹

0 · Reply

Um8a123 Jun. 4 at 8:00 PM

$IRD nice

0 · Reply

signaljumper Jun. 4 at 4:25 PM

$IRD a Close above 4.44 and we have Higher highs and a bullish Signal

0 · Reply

gumby361 Jun. 2 at 2:37 PM

$IRD my average is 3.75 think it will go below

1 · Reply

TheAliAbdul Jun. 2 at 2:03 PM

$IRD so weak recently, if it breaks through the support at $3.96 we could see sub $3 again. Planning to take profit if it gets to $3.50.

1 · Reply

Just_playin_around45 Jun. 1 at 10:35 PM

$IRD back in here for the next leg up.

0 · Reply

History101 Jun. 1 at 1:08 AM

$IRD https://ir.stockpr.com/opusgtx/sec-filings-email/content/0001140361-25-000467/ef20041180_8ka.htm

0 · Reply

History101 Jun. 1 at 1:07 AM

$IRD funny, there were over 18k watching OCUP, but now that OCUP = IRD, only 483 watching on 5/31/2026

0 · Reply

Opus Genetics registers to sell 2.68M shares of common stock for holders

Jun 5, 2026, 8:00 AM EDT - 3 days ago

Opus Genetics Registration statement: Registration filing

2026-06-04T10:16:57.000Z - 4 days ago

Opus Genetics initiated with a Buy at Guggenheim

2026-06-03T17:55:11.000Z - 5 days ago

Opus Genetics management to meet with Citizens

Jun 3, 2026, 8:45 AM EDT - 5 days ago

Opus Genetics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:00 AM EDT - 6 days ago

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

May 30, 2026, 7:00 AM EDT - 9 days ago

Opus Genetics Slides: Investor presentation

May 28, 2026, 4:01 PM EDT - 11 days ago

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 27, 2026, 8:00 AM EDT - 12 days ago

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

2026-05-21T10:33:45.000Z - 18 days ago

Opus Genetics initiated with an Outperform at Leerink

2026-05-21T10:17:22.000Z - 18 days ago

Opus Genetics initiated with an Outperform at Leerink

May 19, 2026, 11:00 AM EDT - 20 days ago

Opus Genetics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 17, 2026, 7:00 AM EDT - 22 days ago

Opus Genetics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 26 days ago

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

2026-05-13T09:57:18.000Z - 26 days ago

Opus Genetics price target lowered to $11 from $12 at Citizens

2026-05-12T12:00:32.000Z - 27 days ago

Opus Genetics reports Q1 EPS (75c), consensus (14c)

May 12, 2026, 7:00 AM EDT - 27 days ago

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 27 days ago

Opus Genetics Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

2026-05-04T21:16:00.000Z - 5 weeks ago

Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program

May 4, 2026, 4:30 PM EDT - 5 weeks ago

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

2026-04-30T13:56:08.000Z - 5 weeks ago

Opus Genetics price target raised to $10 from $9 at B. Riley

2026-04-28T08:45:12.000Z - 5 weeks ago

Opus Genetics initiated with an Outperform at Citizens

2026-04-27T19:55:56.000Z - 6 weeks ago

Opus Genetics management to meet with Piper Sandler

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Opus Genetics Registration statement: Registration filing

2026-04-14T14:50:14.000Z - 7 weeks ago

Opus Genetics management to meet with B. Riley

$Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting$

Apr 10, 2026, 6:59 AM EDT - 2 months ago

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 6, 2026, 7:00 AM EDT - 2 months ago

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

2026-03-30T10:22:42.000Z - 2 months ago

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T10:10:51.000Z - 2 months ago

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

Mar 24, 2026, 7:00 AM EDT - 2 months ago

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Mar 23, 2026, 8:00 AM EDT - 2 months ago

Opus Genetics Proxy statement: Proxy filing

Mar 16, 2026, 7:11 PM EDT - 3 months ago

Opus Genetics Slides: Corporate presentation

2026-03-16T11:41:19.000Z - 3 months ago

Oppenheimer bullish on Opus Genetics, initiates with an Outperform

2026-03-16T10:32:04.000Z - 3 months ago

Opus Genetics initiated with an Outperform at Oppenheimer

2026-03-13T21:00:32.000Z - 3 months ago

Opus Genetics files to sell 7.37M shares of common stock for holders

Mar 13, 2026, 8:00 AM EDT - 3 months ago

Opus Genetics Registration statement: Registration filing

2026-03-12T12:21:25.000Z - 3 months ago

Opus Genetics price target raised to $10 from $8 at Wedbush

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Opus Genetics Proxy statement: Proxy filing

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Opus Genetics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Opus Genetics Annual report: Q4 2025

2026-03-10T11:06:29.000Z - 3 months ago

Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Mar 3, 2026, 8:00 AM EST - 3 months ago

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Feb 27, 2026, 10:10 AM EST - 3 months ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Feb 25, 2026, 6:59 AM EST - 3 months ago

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Feb 13, 2026, 7:30 AM EST - 4 months ago

Opus Genetics Announces $25 Million Private Placement

Feb 2, 2026, 8:00 AM EST - 4 months ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Jan 27, 2026, 7:00 AM EST - 4 months ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 15, 2026, 11:15 AM EST - 5 months ago

Opus Genetics Transcript: 44th Annual J.P. Morgan Healthcare conference

Jan 8, 2026, 7:00 AM EST - 5 months ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Dec 16, 2025, 4:01 PM EST - 6 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 7:00 AM EST - 6 months ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 9, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Nov 20, 2025, 8:00 AM EST - 7 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 13, 2025, 7:00 AM EST - 7 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 12, 2025, 7:00 AM EST - 7 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 7 months ago

Opus Genetics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Opus Genetics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 7 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Oct 14, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 2, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Opus Genetics Transcript: Study result

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Opus Genetics Press release: Study result

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Opus Genetics Slides: Study result

Sep 30, 2025, 7:00 AM EDT - 8 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

$Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Aug 27, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 18, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Opus Genetics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Opus Genetics Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 23, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 3, 2025, 4:30 PM EDT - 1 year ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Transcript: Investor update

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Press release: Investor update

Jun 26, 2025, 6:55 AM EDT - 1 year ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

$Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions$